Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tigemonam, an oral monobactam.

N X Chin1, H C Neu

  • 1Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York 10032.

Antimicrobial Agents and Chemotherapy
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postantibiotic effect of ceftibuten on respiratory pathogens.

The Pediatric infectious disease journal·1995
Same author

Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability--a rationale for dosing programs.

The Pediatric infectious disease journal·1995
Same author

In vitro activity of SCE-2787, a new cephalosporin with potent activity against Pseudomonas aeruginosa and members of the family Enterobacteriaceae.

Antimicrobial agents and chemotherapy·1994
Same author

Emerging trends in antimicrobial resistance in surgical infections. A review.

The European journal of surgery. Supplement. : = Acta chirurgica. Supplement·1994
Same author

Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Drugs·1993
Same author

Gemfibrozil enhances the listeriacidal effects of fluoroquinolone antibiotics in J774 macrophages.

The Journal of experimental medicine·1992

Tigemonam, an oral monobactam antibiotic, shows broad-spectrum activity against many Gram-negative bacteria, including resistant strains. It is effective against Enterobacteriaceae and Haemophilus, but not Pseudomonas or Acinetobacter.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Antibiotic resistance is a growing global health concern.
  • Novel antimicrobial agents are needed to combat resistant bacterial infections.
  • Monobactams represent a class of antibiotics with potential therapeutic applications.

Purpose of the Study:

  • To evaluate the in vitro antibacterial activity of tigemonam.
  • To determine the spectrum of activity and potency of tigemonam against various bacterial pathogens.
  • To assess tigemonam's activity against bacteria resistant to other antibiotics and its effect on beta-lactamases.

Main Methods:

  • In vitro susceptibility testing using minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays.

Related Experiment Videos

  • Testing against a wide range of clinically relevant bacterial strains, including Gram-negative and Gram-positive bacteria.
  • Evaluation of tigemonam's activity against beta-lactamase-producing strains and its effect on beta-lactamase enzymes.

    • Main Results:

    • Tigemonam demonstrated potent in vitro activity against the majority of Enterobacteriaceae, including Escherichia coli and Klebsiella spp., at concentrations ≤1 µg/mL.
    • It was also effective against Haemophilus spp., Neisseria spp., and Branhamella catarrhalis at concentrations ≤0.25 µg/mL.
    • Tigemonam exhibited activity against strains resistant to trimethoprim-sulfamethoxazole and gentamicin, and was not hydrolyzed by common plasmid or chromosomal beta-lactamases, although it inhibited some beta-lactamases without inducing them.

    Conclusions:

    • Tigemonam is a promising orally administered monobactam with broad-spectrum activity against many Gram-negative pathogens.
    • Its efficacy against antibiotic-resistant strains and its stability against common beta-lactamases suggest potential clinical utility.
    • Further investigation into tigemonam's pharmacokinetic and pharmacodynamic properties is warranted.